United States set
language
Menu Shopping cart $0 Search
Distributed product

Human IGF-2 ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Insulin-Like Growth Factor 2
  • Species:Human
Cat. No. Size Price


E30 96 wells (1 kit) $626,25
PubMed Product Details
Technical Data

Cat # changed from RMEE30 to E30

Type

Sandwich ELISA, Biotin-labelled antibody

Description

This enzyme immunoassay kit is suited for measuring IGF-II, human Insulin-like Growth Factor-II, in human serum and plasma for diagnostic and scientific purposes.

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate

Sample Requirements

10 μl

Shipping

On blue ice packs. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

0.45-9 ng/ml

Limit of Detection

0.06 ng/ml

Intra-assay (Within-Run)

CV < 10%

Inter-assay (Run-to-Run)

CV < 10%

Specificity

IGF-I, a homologous molecule to IGF-II, was diluted in three different concentrations (250,750, 1250 ng/mL) and tested with the IGF-II ELISA. None of the samples gave a significant

Note

The kits are CE-IVD certified and intended for professional use.

Summary

Features

  • European Union: for in vitro diagnostic use
  • Rest of the world: for research use only!
  • duration: 3h
  • calibrated against the International Standard: WHO NIBSC 96/538
  • Inter- and Intra-Assay CV < 10%
  • 5 single Calibrators: 0.45 - 9 ng/mL, lyophilized, human recombinant IGF-II
  • 2 Controls, lyophilised
  • limit of detection 0.06 ng/mL

Research topic

Growth hormone and factor-related products

Summary

The insulin-like growth factors (IGF)-I and –II play a pivotal role in the regulation of proliferation and differentiation of several tissue types (1-3). IGF-I also called Somatomedin C (4) has a molecular weight of 7.469 kDa (5). Its expression is mainly regulated by Growth Hormone and nutrition (6). But several hormones and peptide factors are known to influence IGF-II synthesis in different tissues. Bioavailability of the IGFs is regulated by specific binding proteins (IGFBP). Beside the high affinity Insulin-like Growth Factor Binding Proteins 1-6, IGFs are also bound be IGFBP-related Proteins (7, 8, 22). These binding proteins bind IGF-I and IGF-II with the same affinity or prefer IGF-II (9, 10). Direct measurement of IGFs in serum samples without pretreatment results in false values because of the extremely slow dissociation of the IGF/IGFBP complexes during the assay incubation only a part of the IGF-II in the specimen can bind to the antibodies and be detected. Therefore, various techniques were applied to physically separate IGF-II from its binding proteins before measurement, including (a) size exclusion chromatography under acidic conditions, (b) solid-phase extraction and (c) acid-ethanol extraction (2, 12, 13) These techniques, however, are either inconvenient or time-consuming or give incomplete and notreproducible recoveries. This assay is easy, fast and results do not depend on the binding protein concentration of the sample. It is based on the high specificity of the employed antibodies for IGF-II. There is virtually no cross-reactivity with IGF-I. This allows the separation of IGF-II from the binding proteins by acidification and blocking of the free binding proteins with IGF-I. Thus, the endogenous IGF-II is free in solution (15, 21, 23). Indication Scientific studies in the context of neonatal hypertrophy or hypotrophy (IGF-II is a fetal growth factor) and malignancy (IGF-II is an oncogenic growth factor). Age-related reference values are shown in Table 1. IGF-II appears to be suitable for differential diagnosis in various malignant diseases. For example, IGF-II can be used to differentiate between adrenocortical tumors and adenomas. In prostate cancer, too, tumor staging and the differentiation between carcinoma and hyperplasia can be improved by measuring IGF-II in serum (24, 25). Recent results from neurology show that the IGF system is also important in the development of Alzheimer's and Parkinson's disease (26).

Related Products Docs